Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. (AKBA) vs Emergent Biosolutions Inc. (EBS)

Akebia Therapeutics, Inc. and Emergent Biosolutions Inc. are both Drug Manufacturers Specialty & Generic companies. Emergent Biosolutions Inc. is the larger, with a market value of $347.1M against $254.7M — 1.4× the size. Akebia Therapeutics, Inc. grew revenue faster over the last twelve months: 7.52% against −9.56%. Akebia Therapeutics, Inc. has the higher net margin (−13.5% vs −23.0%) and the higher return on invested capital (0.00% vs −5.27%). Across the 20 metrics below, Akebia Therapeutics, Inc. leads on 12 and Emergent Biosolutions Inc. on 8.

Valuation

Metric AKBA EBS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.11 0.45 2.25
P/B 9.70 1.03 1.90
Price to free cash flow 6.03 4.07 16.54
EV/EBITDA n/m 21.47 12.29
EV/Sales 0.62 1.03 2.56
Earnings yield (12.00%) (50.66%) (2.99%)
Free cash flow yield 16.59% 24.57% 0.00%

Profitability

Metric AKBA EBS Drug Manufacturers Specialty & Generic median
Gross margin 79.63% 55.87% 53.94%
Operating margin (6.90%) (8.57%) 0.00%
Net margin (13.54%) (22.96%) 0.00%
Free cash flow margin 18.38% 11.18% 0.00%
Return on equity (109.38%) (40.29%) (0.40%)
Return on assets (8.53%) (13.95%) (3.32%)
Return on invested capital 0.00% (5.27%) 0.00%

Growth

Metric AKBA EBS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 7.52% (9.56%) 10.01%
EPS growth (last fiscal year) 93.94% 125.83% —
Revenue growth, 5-year CAGR (4.33%) (13.74%) 6.74%
Net income growth, 5-year CAGR 0.00% (29.64%) 0.00%

Health

Metric AKBA EBS Drug Manufacturers Specialty & Generic median
Debt to equity 1.98 1.70 0.05
Current ratio 1.43 5.42 2.31
Net debt to EBITDA (5.51) 1.76 0.85

Dividend

Metric AKBA EBS Drug Manufacturers Specialty & Generic median
Dividend yield — 0.79% 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AKBA EBS Drug Manufacturers Specialty & Generic median
Market cap 254.66m 347.12m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack